S&P Futures
3,902.00 +4.25 (+0.11%) Dow Futures
31,241.00 +39.00 (+0.12%) Nasdaq Futures
11,838.00 -40.25 (-0.34%) Russell 2000 Futures
1,771.50 -3.40 (-0.19%) Crude Oil
110.35 +0.46 (+0.42%) Gold
1,845.10 +3.90 (+0.21%)
Cellectis S.A. (CLLS)
Chart Events
Performance Outlook
| Previous Close | 3.9300 |
| Open | 3.8900 |
| Bid | 3.6000 x 1300 |
| Ask | 3.8100 x 1100 |
| Day's Range | 3.7200 - 3.8900 |
| 52 Week Range | 2.8500 - 16.5300 |
| Volume | |
| Avg. Volume | 226,980 |
| Market Cap | 179.497M |
| Beta (5Y Monthly) | 2.27 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.9200 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.40 |
- GlobeNewswire
Cellectis’ Annual Shareholders’ General Meeting to be Held on June 28, 2022
NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its combined general meeting on June 28, 2022 at 2:30 p.m. CET at the Company's offices at 8 rue de la Croix Jarry (4th floor) 75013 Paris, France. The notice announcing the General Meeting details the agenda and modalities of participation fo
- Motley Fool
Why Cellectis' Shares Rose 22.7% This Week
Shares of Cellectics (NASDAQ: CLLS), a clinical-stage biopharmaceutical company that specializes in oncology, rose 22.7% this week, according to data from S&P Global Market Intelligence. The company released research data on its new universal CAR (Chimeric Antigen Receptors) T-cell HEAL platform at The American Society of Gene and Cell Therapy's (ASGCT) annual meeting on Monday. In the report, the company said its novel immune-evasive CAR T-cell (ΔTRACCARΔB2MHLAE) showed preclinical promise in fighting acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL).
- GlobeNewswire
Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT
NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today will present its first research data on the development of a novel universal CAR T-cell with immune-evasive properties using TALEN®-gene editing, at the American Society of Cell and Gene Therapy Annual Meeting (ASGCT) being held on May 16-19, 2022. This
